InRAD international registry for Alzheimer's disease and related dementias
The International Registry for Alzheimer's Disease and Other Dementias (InRAD): An International Registry Observational Study Dedicated to Evaluating Outcomes Data in Alzheimer's Disease
This project will collect routine medical information over time to see how Alzheimer's disease, mild cognitive impairment, and related dementias progress and how current treatments are tolerated in adults.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50000 (estimated) |
| Sex | All |
| Sponsor | Stichting International Registry for Alzheimer's Disease and other Dementias Foundation Academic / other |
| Locations | 1 site (Leuven) |
| Trial ID | NCT07213700 on ClinicalTrials.gov |
What this trial studies
The InRAD Observational Study is a prospective, non-interventional, multinational registry that collects real-world clinical data from adults undergoing diagnostic work-up for or living with Alzheimer's disease. Participating centers record demographics, comorbidities, diagnostic and monitoring tests, medication exposures, cognitive and functional measures, and adverse events during routine care, typically with at least annual visits. Data are pseudonymized and pooled to allow comparison of disease trajectories, treatment safety, and outcomes across countries and regions over many years. Operational management and system support are provided by the InRAD Foundation while individual centers remain the data controllers.
Who should consider this trial
Good fit: Adults undergoing diagnostic work-up for Alzheimer's disease or with a confirmed AD diagnosis (treated or untreated) who receive care at an InRAD-affiliated center and can provide informed consent are eligible.
Not a fit: People who cannot or will not provide informed consent, or who do not attend an InRAD center, are unlikely to receive direct benefit from participation.
Why it matters
Potential benefit: If successful, the registry could improve understanding of long-term disease course and treatment safety, helping clinicians make better care and monitoring decisions for patients with dementia.
How similar studies have performed: Large observational registries and consortia (for example ADNI and national dementia registries) have produced useful insights into progression and treatment effects, so this registry approach is established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Be undergoing diagnostic work-up for Alzheimer's disease (AD), OR * Have a confirmed diagnosis of AD (whether currently treated with an AD-specific treatment, or untreated), * Be attending an InRAD Center, * Have provided informed consent for long-term follow-up Exclusion Criteria: -Any patient or legal representative who is unable or unwilling to provide a signed informed consent form
Where this trial is running
Leuven
- UZLeuven — Leuven, Belgium (Recruiting)
Study contacts
- Study coordinator: Scientific Officer
- Email: office@inradnetwork.org
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.